Partnerships

Bukwang

Bukwang Pharm. Co. (www.bukwang.co.kr), Ltd. is a leading Korean pharmaceutical company listed on the Korean Stock Exchange [KRX:003000]. The company has been in business for over 50 years, and achieved US$150 million in sales in 2020. Sales are primarily derived from products licensed from Europe, the United States, and Japan. The company is currently investing significant resources in R&D to create a robust pipeline of preclinical and clinical agents for the treatment of antiviral diseases, gastrointestinal disorders, CNS disorders and metabolic disease. Bukwang is our partner for JM-010.

BDD Pharma

BDD Pharma Ltd (www.bddpharma.com) is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD’s OralogiK™ technology is a tablet-in-tablet drug delivery system providing timed release, targeted release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK™ technology is protected with granted patents across a number of territories including the US, EU and Japan. Supported by investment from Archangels, the Scottish Investment Bank, Alderley Park Ventures and BioCity Investments, BDD has in-house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans. BDD’s SWIFT adaptive clinical trials integrate formulation development, GMP manufacturing and clinical testing into one streamlined service, offering a more flexible approach than the conventional clinical trial design structure.

University of Copenhagen – Dept. Drug Design and Pharmacology

Contera Pharma has lab facilities and conducts its own research at the Department of Drug Design and Pharmacology (https://drug.ku.dk/) at the Faculty of Health and Medical Sciences at the University of Copenhagen. The department which employs approximately 300 scientific and administrative staff members conducts research and delivers teaching in a wide range of drug-discovery related disciplines and has cross-disciplinary collaborations with Danish and international research institutions and businesses, including clinical hospitals, pharmaceutical and biotech industries, as well as spin-out companies. Dept. Drug Design and Pharmacology is our collaboration partner for the Neuroinflammation research program.

Recent News

September 27, 2022

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…